Harbinger Research Releases Research Report on Vycor Medical, Inc.
MAY 1, 2012 - 13:59 ET
FOR: VYCOR MEDICAL, INC.
BOCA RATON, FL--(Marketwire - May 1, 2012) - Vycor Medical, Inc. (
The report states that Harbinger Research "are initiating coverage of Vycor with a Strong Buy rating and a target price range of $0.05 per share" noting that Vycor's neurosurgical ViewSite Brain Access System leads to "improved clinical outcomes, shorter surgeries, and shorter recovery times; in some cases this product's superior attributes have allowed brain surgeons to successfully perform surgeries that would have otherwise been considered inoperable" and that they are "most excited about the long-term potential of the NovaVision subsidiary, as its products have no real competition and address a global market that could be up to $20B in size." Furthermore they state that "both NovaVision and ViewSite have strong patent protection and backing from the scientific community, and both are FDA 510(k) cleared for sale in the United States."
David Cantor, President of Vycor Medical, stated that management is pleased by the positive outlook for the Company reflected in the report.
About Vycor Medical Inc.:
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (
Vycor Medical's subsidiary, NovaVision, Inc., researches, develops and provides science-driven vision-based neurostimulation therapy and other medical technologies that help to improve sight in patients with neurological vision impairments. The company's proprietary, Visual Restoration Therapy (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury ("TBI"), or other acquired brain injury, and has been 510(k) cleared to be marketed in the US by the FDA. VRT can be prescribed by any ophthalmologist, optometrist, neurologist or physiatrist. NovaVision, through its subsidiary Sight Science, also provides Neuro-Eye Therapy (NeET), aimed at increasing visual sensitivity deep within the field defect. NovaVision also provides a fully portable and ADA-compliant Head Mounted Perimeter (HMP™) which aids in the detection and measurement of visual field deficits
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.